RxDoctor Payments Data

Ehtesham Khalid

Neuromuscular Medicine · New Orleans, LANPI 1528493202

Payments from drug & device makers

$131,950in general payments, 2019–2025

Across 116 payments — averaging $1137.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$50K
  • AstraZeneca$26K
  • Sanofi$21K
  • Johnson & Johnson$12K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • UCB, Inc.$8K
  • plus $4K from 7 others

What the payments were for

  • Consulting fees$57,93971%
  • Speaking & faculty fees$16,20820%
  • Travel & lodging$4,4795%
  • Food & beverage$3,4844%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$28,426
Medicare patients
145
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz16$564,711
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5017$108,270
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$61,023
Droxidopa22$14,365
Riluzole27$3,315
Pyridostigmine Bromide33$2,605
Carbamazepine ErCarbamazepine13$1,219
Baclofen27$341
Pregabalin27$336
Venlafaxine Hcl ErVenlafaxine Hcl33$267
Duloxetine Hcl28$252
Gabapentin33$207
Oxybutynin Chloride ErOxybutynin Chloride16$145
Cyclobenzaprine Hcl24$86
Fluoxetine Hcl15$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$26,307$564,71116 claims
Grifols USA, LLCGamunex-C$150$61,02312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in New Orleans

Where these figures come from

Is this you, or does something look wrong? →